증권
T. Rowe Price to buy fixed income fund manager F/m InvestmentsAs of 31 July 2026, F/m Investments oversaw $19bn in assets.
This Lumentum Insider Sold $1.6 Million in Stock. Here's What Long-Term Investors Should KnowJae Kim reduced direct holdings through a combination of Rule 10b5-1 plan sales and tax withholding transactions, while maintaining $33 million in remaining equity exposure.
3 Things Nvidia Needs to Get Right This WeekEarnings season has been rough for the country's most valuable company lately. Things could be different this time.
Dow Jones Futures: Tariffs In Focus; Nvidia, Warsh AheadGold, biotechs and bitcoin shine bright, but many techs could go either way.
A Tax Strategy So Aggressive It Built the World’s Largest Hedge Fund and Made Losing Money the Hottest Product on Wall StreetCliff Asness spent three decades fuming that taxes destroyed more investor wealth than bad stock picks ever did, so he built a fund that turns losing money into the actual product. What regulators are now calling potentially abusive, his clients are calling the smartest trade on Wall Street.
Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside?Turnarounds in the healthcare sector do not all look the same. Some companies recover because management executes better, launches stronger products, and improves operations, while others do so because the industries they serve begin improving after prolonged downturns. Medtronic (NYSE:MDT) and Thermo Fisher Scientific (NYSE:TMO) are two of healthcare’s most closely watched recovery stories, but […]
The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.Green Thumb Industries is in a strong position to acquire other cannabis companies, but will that happen?
Prediction: Oklo Won't Book Its First Commercial Power Revenue Before 2028The nuclear start-up just proved it can build a reactor in 11 months. Selling electricity from one runs on a different schedule.
Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?Healthcare investors are often faced with a choice between companies that generate steady growth across diversified businesses and those positioned to benefit from improving industry conditions. Abbott Laboratories (NYSE:ABT) and Thermo Fisher Scientific (NYSE:TMO) represent those two approaches. Abbott (NYSE:ABT) continues to deliver broad-based growth across diagnostics, medical devices, and nutrition, while Thermo Fisher (NYSE:TMO) […]
The next big oil trade may have nothing to do with oil stocksA brutal oil shock is creating opportunity in one unlikely sector
Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?Healthcare investors looking for long-term growth don’t always have to choose between fast-growing companies and defensive businesses. Sometimes the more interesting decision is between two high-quality companies that are growing for entirely different reasons. Johnson & Johnson (NYSE:JNJ) continues to benefit from the breadth of its pharmaceutical and medical technology businesses, while Thermo Fisher’s (NYSE:TMO) […]
The $70M business behind Ballerina FarmThe $70M business behind Ballerina Farm
Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?Healthcare investors often face a difficult decision when choosing between companies with very different paths to growth. Some businesses are emerging from temporary industry slowdowns, while others continue compounding through durable competitive advantages. Danaher Corporation (NYSE:DHR) and Intuitive Surgical (NASDAQ:ISRG) illustrate that contrast perfectly. Danaher (NYSE:DHR) is beginning to benefit from improving life sciences spending […]
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals CanCould this little-known biotech be a hidden gem?
The “Crummey Letter”: The One-Page Note Families Mail Every December to Keep a Million-Dollar Trust Tax-Free.Most families funding irrevocable trusts lose thousands in gift-tax exclusions every year over a single missing piece of paperwork, and the IRS is under no obligation to warn them.
Goldman Sachs spots huge twist ahead of Nvidia’s earningsAnalysts reveal what could happen to Nvidia shares next, and set expectations for the Q2 report.
Thermo Fisher vs. Intuitive Surgical: Which Premium Healthcare Stock Deserves its Valuation?Premium healthcare stocks often trade at elevated valuations for very different reasons. Thermo Fisher’s (NYSE:TMO) investment case increasingly depends on whether the life sciences industry is emerging from its post-pandemic slowdown, while Intuitive Surgical (NASDAQ:ISRG) continues to hold a dominant position in robotic surgery through factors such as its highly recurring revenue model. Both companies […]
Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?Healthcare investors are beginning to see signs of recovery across several parts of the industry, but not every recovery looks the same. Danaher (NYSE:DHR) is benefiting from improving demand in life sciences after a prolonged post-pandemic slowdown, while Medtronic (NYSE:MDT) is finally beginning to show the results of years of investment in new products and […]
Micron CEO is doubling down on a cycle-free futureMicron says the memory cycle is broken. Its own books once told a different story.
Tesla Maintained Its Majority of the U.S. EV Market in Q2, but That's Not All You Need to KnowIt's a winner in a shrinking U.S. market, and it's not like the company's crushing it outside of the United States either.